Helio Genomics and Quest Diagnostics have partnered to expand access to a blood-based liver cancer test across the U.S.
Starting in April, providers with a Quest account will be able to order HelioLiver, a test designed for early detection of hepatocellular carcinoma, through Quest’s network, according to a March 18 news release shared with Becker’s.
Under the agreement, the test will be available through Quest’s approximately 7,700 patient service centers and integrated into provider workflows, including electronic health record systems. Helio Genomics will continue to perform testing at its laboratory in West Lafayette, Ind.